Replies to post #23370 on Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

Times are a changin' for IPCI Angelo...thnx for the speculative projections

[Amigo Mike]

Angelo,

Assuming a 50-50 split with Mallinckrodt... every 1% of the market that IPCI/MNK capture will be $24 million... or $12 million to IPCI's bottom line... assuming 2.5% penetration IPCI's pure profit would be $30 million a year.

. No expense to IPCI eh ? Pure profit ? Depends on deal. Apparently IPCI wants to be in manufacturing business.

It would be helpful of mgmt to be providing investors more insight into the ANDAs and their current standing with the FDA beyond the boilerplate. Surely the FDA has had contact with IPCI on these applications.

Amigo Mike

[numbersarefun]

AngeloFoca, Glucophage_XR not partnered with Mallinckrodt. IPCI's four generics with low price per pill are not partnered yet. Mallinckrodt picked the three generics left with high price per pill. I would guess to capture 1% of Glucophage, IPCI would have to sell millions of pills at a very low price. IPCI probably could not handle that large of a manufacturing job at its site.

AngeloFoca wrote: "my mistake... Glucophage's XR market is $2.4 Billion.

Assuming a 50-50 split with Mallinckrodt... every 1% of the market that IPCI/MNK capture will be $24 million... or $12 million to IPCI's bottom line... assuming 2.5% penetration IPCI's pure profit would be $30 million a year. "